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between April 2010 and May 2011. PEVAR procedures with adjunctive ‘pre-close’ of
the common femoral arteries (CFAs) targeted for large sheath access using the ProGlide
or Prostar XL closure devices were performed using the Endologix IntuiTrak System.
All patients were followed procedurally and to 30 days for major adverse events and
access-related vascular complications.
Results: Patients presented at a mean age of 71 years with mean aneurysm sac diameter
of 5.6cm. Pre-close procedural success was 97% (37/38 patients). In one patient,
ProGlide devices failed to achieve ipsilateral CFA hemostasis, leading to bleeding
requiring transfusion and surgical vascular repair. All endovascular repairs were
successful. No mortality or major adverse events occurred. Other pre-close related
complications occurring within 30 days included pseudoaneurysm, lower extremity
ischemia, and blood transfusion.
Conclusion: PEVAR with adjunctive ‘pre-close’ techniques using the ProGlide or
Prostar XL devices is safe and feasible as applied in this multicenter experience.
Continued evaluation in a prospective, randomized trial is warranted.
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Background: Survival estimates of patients with aortic dissection commonly come
from tertiary care centers; such estimates may be biased by referral and selection bias.
The survival rate of unselected patients with aortic dissection in the community remains
poorly defined.
Methods: Aortic dissection cases where identified from the Kaiser Permanente-
Registry of Aortic Dissections (KP-RAD). This population-based registry was designed
to capture consecutive cases of aortic dissections occurring among the approximately
3,000,000 health plan members in Southern California. Aortic dissections were
categorized as either type A or B. The endpoint for the analysis was all-cause mortality.
The failure rate by dissection type was compared using the Kaplan-Meier method.
Results: There were 347 aortic dissection cases identified. Of these, 141 were type A
aortic dissection and 206 were type B aortic dissection. The mean age of the cohort
was 64 ± 16 years and 36% were female. The 30-day mortality for type A dissections
was 10.0% and 4.4% for type B dissections. However, at 6 months, the event rates
were similar; the mortality in the type A dissection group was 12.3% compared to
11.7% in the type B dissection group. The mortality rate by dissection type is shown
in the figure.
Conclusion: Type A aortic dissections are associated with higher 30-day mortality
compared to type B dissections. However, by 6-months the mortality rate is similar in
both groups. Very close follow-up in the first six months after aortic dissection seems
warranted.
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Background: Endovascular treatment of the superficial femoral artery (SFA) is
associated with an inflammatory response correlated with restenosis. Dexamethasone
delivered into the vessel adventitia at the treatment site may abate post-intervention
inflammation and reduce restenosis rates.
Methods: Patients with TASC II A, B, and C disease of the SFA were eligible for this
study. Following successful intervention, an adventitial micro-infusion catheter,
(Bullfrog®, Mercator MedSystems, San Leandro, Calif.), was advanced over a 0.014”
wire to the treated segment. Its micro-needle (0.9 mm long x 140 μm diameter) was
deployed into the adventitia to deliver dexamethasone (DEX, 4 mg/ml) mixed with
iodixanol contrast agent (80:20 ratio), providing fluoroscopic visualization. In total, 5
mg of DEX was infused per 5 cm of treated artery.
Results: Six patients have been enrolled in this study (mean age, 66 years). Mean
lesion length was 88 mm and included 3 TASC II As, 2 Bs, and 1 C lesion (4/6 were
chronic total occlusions). Each case resulted in complete cylindrical distribution of
DEX in the adventitia around the target artery with 100% technical success and no
adverse events, Table 1. Treatment required an average of 2.7 injections per patient.
Conclusion: Adventitial drug delivery is a feasible alternative to luminal or intimal
delivery modes. The micro-infusion catheter is a safe and efficient method to achieve
adventitial drug delivery. Further study is warranted to determine if DEX treatment of
the SFA decreases restenosis rates.
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Background: Acute type A aortic dissection still carries a 25% mortality based on
international registries, while mortality for complicated type B dissection has been
significantly reduced with the advent of thoracic endovascular aortic repair (TEVAR).
The purpose of this study was to simulate type A dissection by computational fluid
dynamics (CFD) to determine the relationship of tearing force to dissection
propagation, and to determine anatomic feasibility of TEVAR in patients with acute
type A dissection by characterizing primary intimal tears using 64-multislice
computerized tomography (MSCT).
Methods: Computational models of aortic dissection were constructed. Dissection
propagation was represented in single- and double-entry tear models. Impact of
pressure field distribution on tearing force was determined. On the clinical side,
radiology database was screened for acute type A aortic dissection on 64-slice CT
scans. Seventeen patients were reviewed for physical characteristics of intimal tears.
Potential obstacles for TEVAR were sought.
Results: On CFD, tearing force for dissections with a single entry tear was
approximately proportional to the rate of pressure rise and the second power of
dissection length. Introduction of a second tear distally along the dissection away from
the primary entry tear significantly reduced tearing force. On MSCT, ascending aorta
(29%) and sinotubular junction (29%) were the most frequent regions where intimal
tears originated. Location of intimal tears in nearly 75% of patients was inappropriate
for TEVAR, and 94% of patients did not have sufficient proximal or distal landing
zone required for secure fixation. Only one patient met all technical criteria for TEVAR
using currently available devices.
Conclusion: TEVAR for aortic dissection should ideally cover both entry and re-entry
tears to reduce risk of propagation. Location of intimal tear, aortic valve insufficiency,
and aortic diameter were major factors limiting use of TEVAR for acute type A
dissection. Available stents used to treat type B dissection do not address anatomic
constraints present in type A dissection in the majority of cases, such that new device
development would be required.
TCT-576
Use of Orbital Treatment in a High Volume Clinical Practice Modifies Non-
Compliant Plaque to Deliver Durable Long-Term Results
Prakash Makam, Ricardo Guedes
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Background: Resistant fibrotic and calcified plaques are a major limitation in the
treatment of peripheral arterial disease (PAD). Balloon angioplasty typically ranges 8-
16 atms in these plaques, and subsequent dissection rates range 40-74%, with bail-out
stent rates as high as 40%. Plaque modification as a first-line endovascular therapy
alters lesion compliance to prevent dissections and the need for stent placement. We
report a single center experience utilizing the next generation orbital technology, called
Predator 360 (Cardiovascular Systems, St. Paul, MN) to evaluate the long-term
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